Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 16/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.48 |
| ▸ | PAK4 | O96013 | 3/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1614086 | 1.00 | MAP3K14 (0.48) | MAP3K14MAP4K4PAK4PIK3CAPRKD1 | |
| SCHEMBL12714856 | 1.00 | MAP3K14 (0.48) | MAP3K14MAP4K4PAK4PIK3CAPRKD1 | |
| SCHEMBL1612639 | 1.00 | MAP3K14 (0.48) | MAP3K14MAP4K4PAK4PIK3CAPRKD1 | |
| SCHEMBL12714854 | 0.95 | MAP3K14 (0.47) | MAP3K14MAP4K4PAK4PRKD1 | |
| SCHEMBL1613474 | 0.95 | MAP3K14 (0.47) | MAP3K14MAP4K4PAK4PRKD1 | |
| SCHEMBL12714847 | 0.95 | MAP3K14 (0.47) | MAP3K14MAP4K4PAK4PRKD1 | |
| SCHEMBL1612136 | 0.95 | MAP3K14 (0.47) | MAP3K14MAP4K4PAK4PRKD1 | |
| SCHEMBL1612535 | 0.91 | MAP3K14 (0.47) | MAP3K14MAP4K4PAK4 | |
| SCHEMBL13575151 | 0.90 | MAP3K14 (0.46) | MAP3K14MAP4K4PAK4PRKD1 | |
| SCHEMBL1612537 | 0.90 | MAP3K14 (0.46) | MAP3K14MAP4K4PAK4PRKD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2011-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | NFKBIA, MAP3K1, MAP3K2 | MAP3K14 17/4885MAP4K4 57/4885PAK4 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.